IMBRUVICA(R) (ibrutinib) Supplemental New Drug Application Accepted for Review by U.S. FDA with Potential to Broaden Treatment Use as a Combination Treatment Option with Rituximab in Waldenström's Macroglobulinemia (WM), A Rare Form of Blood Cancer

The filing is based on data from the Phase 3 iNNOVATE study, which suggest that IMBRUVICA plus rituximab may improve outcomes across all lines of Waldenström's macroglobulinemia (WM) treatment, including patients with prior lines of therapy and variou... Biopharmaceuticals, Oncology, FDA AbbVie, IMBRUVICA, ibrutinib, Waldenström's Macroglobulinemia
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news